CERE / Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain more_horizontal

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain more_horizontal

Cerevel said it is experiencing delays in some of its clinical trials. The company appointed a new CEO in June. more_horizontal

CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain more_horizontal

Cerevel has some interesting data in various CNS indications. However, the company has a very high valuation. It seems a lot of the company's potentia more_horizontal

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Calistri - Vic more_horizontal

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain more_horizontal

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indicati more_horizontal